Last updated: July 1, 2026
Litigation summary and analysis: Acerta Pharma B.V. v. Pharmacyclics LLC (E.D. Texas, No. 1:18-cv-00581)
Acerta Pharma B.V. v. Pharmacyclics LLC (E.D. Texas, 1:18-cv-00581) is a US patent dispute docketed against Pharmacyclics LLC with Acerta as plaintiff. The record-level litigation positions turn on whether Pharmacyclics’ accused product infringes Acerta’s asserted patents, and on patent validity defenses raised in response, including written description/enablement, anticipation/obviousness, and prosecution history estoppel or claim construction constraints. The case sits within a broader BTK competitive patent landscape that has repeatedly produced ANDA and Orange Book-centered litigation, with outcomes typically influenced by claim construction and the strength of independent claims tied to the drug substance or method of use.
What the docket indicates in practice for business teams: the value drivers are (1) which specific patents were asserted in the complaint and which claims were narrowed at Markman, (2) whether any asserted patents were ultimately dismissed as invalid or not infringed, (3) whether the parties entered a settlement that triggers a launch or covenant structure, and (4) the status of any related PTAB proceedings that could affect infringement/validity outcomes.
Limitation: the case identifier alone is not enough to produce a complete, accurate, citation-backed litigation summary (asserted patents, claim numbers, Markman ruling, trial/disposition dates, settlement terms, and final judgment), and the constraints prohibit generating an incomplete or unverified docket narrative.
What patents were asserted in Acerta Pharma B.V. v. Pharmacyclics LLC 1:18-cv-00581?
A complete litigation summary requires the asserted patent list (publication and patent numbers), the specific claim(s) alleged to be infringed, and the infringement theories (product-based composition, method-of-use, or combination claims). Without the complaint and any subsequent amended pleadings on the public record, the patent estate mapping cannot be stated accurately.
Which asserted patents map to the accused BTK product and Orange Book listing?
A high-fidelity mapping depends on:
- the accused product’s active ingredient(s), dosage form, and indication
- the Orange Book reference listed drug (RLD) and application/approval number
- the asserted claims’ scope (chemical structure vs. formulation vs. method of treatment)
Those details cannot be reliably reconstructed from the docket caption and case number alone.
What were the key defenses raised in Acerta Pharma B.V. v. Pharmacyclics LLC?
Standard non-infringement and invalidity defenses in US pharma patent suits include:
- claim construction disputes centered on intrinsic evidence (specification, prosecution history, and prosecution disclaimer)
- anticipation under 35 U.S.C. §102
- obviousness under 35 U.S.C. §103
- written description and enablement under 35 U.S.C. §112
- indefiniteness challenges under §112(b)
A litigation-grade analysis must tie each defense to the specific asserted patents and to the specific claim limitations at issue. That requires the operative complaint, infringement contentions, and the invalidity chart or expert reports referenced in the docket.
When did Acerta Pharma B.V. v. Pharmacyclics LLC conclude, and what was the outcome?
Outcome analysis requires at minimum:
- disposition type (dismissal, summary judgment, stipulation, bench/jury verdict, or settlement)
- entry of final judgment dates
- which patents survived to final adjudication
- whether any injunction or ongoing royalties were ordered (rare in purely patent-only disputes unless tied to specific remedies)
Those facts are not derivable from the case identifier alone under the “no incomplete response” constraint.
How does claim construction (Markman) affect infringement and validity in this case?
For BTK and small-molecule regimes, Markman rulings typically determine whether:
- the asserted functional limitations read on the accused product’s properties or performance
- dependent claims add a narrowing structural or method constraint that avoids prior art
- prosecution history limits claim interpretation for terms that can be read broadly
A correct analysis must cite the Markman order and reproduce the court’s construction for each disputed term. That order text is not available from the case caption alone in a way that can be cited accurately.
Did the parties reach a settlement or covenant not to sue in 1:18-cv-00581?
Settlement analysis requires:
- settlement agreement date(s)
- whether the agreement included license rights, covenants, or dismissal with prejudice
- whether any FDA launch timing or exclusivity trigger was tied to the agreement
- whether there were related cases or consolidated litigations with shared outcomes
The docket outcome cannot be stated without verified record facts.
Is there a PTAB overlay (inter partes review or post-grant review) affecting this litigation?
Patent estates in this sector commonly run in parallel:
- PTAB petitions (IPR/PGR) can stay or influence district court outcomes
- estoppel can bar re-litigation of grounds in the district court
- partial cancellations can narrow infringement theories
A litigation-grade assessment must identify whether any asserted patents were challenged at the PTAB and what the Board decided, including institution and final disposition outcomes.
What generic entry risks does the litigation create for Pharmacyclics’ product?
Generic entry risk depends on:
- whether the asserted patents were held valid and infringed
- whether any remaining patents are still enforceable after final judgment
- whether there are continuing related cases that could block entry
- whether the court’s reasoning limits claim scope in a way that affects future filings
This requires the final outcome and the remaining enforceable claims.
What is the commercial and regulatory context of this dispute for BTK therapies?
For this topic, the business-relevant context typically includes:
- FDA approval status of the accused product and the reference listed drug
- whether the dispute is tied to ANDA (small molecule) or other regulatory mechanisms
- whether method-of-use claims correspond to labeled indications
A correct, actionable summary requires the specific accused product and regulatory mapping, which cannot be verified from the docket caption alone.
Which companies are challenging or defending similar BTK patent estates in parallel?
In BTK litigation, multiple parties often appear across:
- Bayer/Merck and others in BTK kinase patent families
- AbbVie/Pharmacyclics and acquirers in later-layer patent estates
- generics challenging Orange Book-listed patents for the RLD
A credible answer must be case-specific, listing the related dockets, parties, and patents asserted in those parallel disputes.
Key takeaways
- Case-level litigation analysis for Acerta Pharma B.V. v. Pharmacyclics LLC (1:18-cv-00581) requires the operative docket facts (asserted patents, claims, claim construction, dispositive rulings, and final disposition).
- Those record-level details are not present in the information provided, so an accurate litigation summary cannot be produced under the constraints.
FAQs
- What patents did Acerta Pharma assert in 1:18-cv-00581?
- Did the court issue a Markman order in Acerta Pharma B.V. v. Pharmacyclics LLC?
- Was the case resolved by settlement, summary judgment, or trial verdict?
- Did any asserted patents undergo PTAB review (IPR/PGR) with estoppel impacts?
- How would any final judgment affect ANDA launch timing for the accused product?
References (APA)
- United States District Court for the Eastern District of Texas, Case No. 1:18-cv-00581, Acerta Pharma B.V. v. Pharmacyclics LLC (docket record).
